about
PML nuclear bodiesA drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discoveredArsenic trioxide for the treatment of acute promyelocytic leukaemiaTRIM family proteins: retroviral restriction and antiviral defenceProteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cellsThe human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activitiesFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRetinoic acid and arsenic for treating acute promyelocytic leukemiaThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesCytoplasmic PML function in TGF-beta signallingArsenic exposure predicts bladder cancer survival in a US populationIncreased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockadeThe cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenesIn vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosisArsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment.Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.Influence of arsenate and arsenite on signal transduction pathways: an updateArsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.Acute and chronic arsenic toxicity.Near infrared imaging of EGFR of oral squamous cell carcinoma in mice administered arsenic trioxideAll-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaThe PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideIndividual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms.Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism.Body language: the function of PML nuclear bodies in apoptosis regulation.Nuclear organization in genome stability: SUMO connections.Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis.Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide.PML nuclear bodies and apoptosis.Determination of arsenic species: a critical review of methods and applications, 2000-2003.Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation.Nuclear structure in cancer cells.Arsenic trioxide in the treatment of haematological malignancies.Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytes.In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.Native musk and synthetic musk ketone strongly induced the growth repression and the apoptosis of cancer cells.
P2860
Q22065791-141FC435-9BBB-4423-8BBA-BEF9751CB3B8Q23671266-1D696625-CD0C-45A6-B18A-CD5942AE5C49Q24239914-720E0E4F-BCB1-4202-85DC-9C00291560C4Q24329175-B08B9E56-98FB-4C28-98A6-0A42557FBD82Q24337180-E51ACB54-C838-4CBE-BB9A-8884121C7A85Q24561930-D5E470D5-C690-4FA8-8E2E-A1C49E3C1A89Q24605527-24C996D6-073A-4BF3-B822-1541C1B592F6Q24809165-2B0AB5DC-0165-4ED6-8F18-C296AAED6468Q26853348-A2E33CCF-AE39-4925-B9A8-2CEEF2BFD655Q28281152-70C130E9-048F-4D21-8703-ADEBC1C08213Q28397390-535DE64A-8985-4FDC-9410-28A03F7DD471Q28539684-27613554-7407-4DCF-8161-F2CFA7251CF1Q28649653-C6AD116D-30CE-446C-B907-9D01392A7223Q33185196-C20711B3-2168-4FDB-A5A2-44059F6FA6DDQ33203379-847253AE-82EF-4EB1-BC42-B1B214B6D36DQ33551142-FDC4C3EB-6F0C-4032-A3CD-F8ADC2842589Q33640702-1136CD5B-FC0C-494C-8AD3-D58230208E38Q33836409-37AC3DB5-7168-4F25-B86C-3DFF63FF21CDQ34024633-EE5A2E36-9FF2-41CC-878B-A1CFB1B6E459Q34185125-62322C2B-A620-4D55-944F-333E8F856D34Q34219547-825736CA-B441-4200-9651-AFFEA4621E0DQ34430979-B100BDCB-29CE-435F-8015-169D4F17ABACQ34546653-222385D3-F290-4CDD-A565-1200AB1C46CFQ34548159-4AA1A1B0-836D-422B-BB00-48D89955FD8EQ34609485-C03C6AFF-0764-4BE9-A481-1DD48B5BC862Q35079230-A703A21D-E54C-4555-88DC-88404E354D0CQ35147292-1C3CABE2-884B-4BA6-A4A9-BC217A65521AQ35204844-D5804829-A111-49F1-9FDC-45F00B687792Q35348095-1D2885FF-4EA1-4443-881B-FD6B87CB1B9DQ35537909-6072411B-82CA-4943-8008-3C0571AA99BCQ35560264-88D4D491-ECC3-432E-B538-2523600C39CDQ35640744-CBBC3542-E7F0-41A9-B838-7833739443D8Q35743115-68D83319-558E-42DD-A5F7-FB2A32AFABACQ35759588-87AEF87F-8D3B-45DD-A38B-1FBC5D632B8BQ35847861-44535AD0-C3F9-45D0-8135-422182F8FC9AQ35877173-D40B8FA8-BD8E-49CC-80A4-2D21EACAA126Q35925650-2E74DEE0-7C9E-4C51-B535-59057877AF77Q35939136-B4E9054A-861C-4B81-AAED-5820882ABAC0Q35994968-C477B3BF-83B5-4116-BE8D-9586CBD3B909Q36216586-12E9D572-36FC-4EF0-911B-3912027999D4
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
How acute promyelocytic leukaemia revived arsenic.
@ast
How acute promyelocytic leukaemia revived arsenic.
@en
How acute promyelocytic leukaemia revived arsenic.
@nl
type
label
How acute promyelocytic leukaemia revived arsenic.
@ast
How acute promyelocytic leukaemia revived arsenic.
@en
How acute promyelocytic leukaemia revived arsenic.
@nl
prefLabel
How acute promyelocytic leukaemia revived arsenic.
@ast
How acute promyelocytic leukaemia revived arsenic.
@en
How acute promyelocytic leukaemia revived arsenic.
@nl
P2093
P356
P1476
How acute promyelocytic leukaemia revived arsenic.
@en
P2093
Valérie Lallemand-Breitenbach
P2888
P304
P356
10.1038/NRC887
P407
P577
2002-09-01T00:00:00Z
P6179
1022474333